1. Applegate, C. D. and Tecott, L.H., Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis, Experimental Neurology, 154(2) (1998) 522–530.
2. Backstrom, J.R., Price, R.D., Reasoner, D. T. and Sanders-Bush, E., Deletion of the serotonin 5-HT2C receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses, Journal of Biological Chemistry, 275(31) (2000) 23620–23626.
3. Bagdy, G., Graf, M., Anheuer, Z.E., Modos, E. A. and Kantor, S., Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635, International Journal of Neuropsychopharmacology, 4(4) (2001) 399–408.
4. Becamel, C., Alonso, G., Galeotti, N., Demey, E., Jouin, P., Ullmer, C., Dumuis, A., Bockaert, J. and Marin, P., Synaptic multiprotein complexes associated with 5-HT2C receptors: a proteomic approach, EMBO Journal, 21(10) (2002) 2332–2342.
5. Becamel, C., Figge, A., Poliak, S., Dumuis, A., Peles, E., Bockaert, J., Lubbert, H. and Ullmer, C., Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1, Journal of Biological Chemistry, 276(16) (2001) 12974–12982.